TB-500: Research & Laboratory Overview

Introduction

"TB-500" is a commercial and research-community label rather than a formal scientific name. It is usually applied to synthetic material related to thymosin β4 (Tβ4), a small, highly conserved protein found in most mammalian cells. The scientific literature is largely written about Tβ4 itself, or about specific fragments of it, so careful terminology matters when reading research.

What Is TB-500?

Thymosin β4 is a 43-amino-acid, N-terminally acetylated protein (≈4.9 kDa). It is one of the most abundant intracellular peptides in many cell types and is best known as the principal G-actin–sequestering molecule — it binds monomeric actin and regulates the pool available for filament assembly.

Materials sold or described as TB-500 vary. Some correspond to the full-length Tβ4 sequence; others refer to the central actin-binding motif (commonly cited as LKKTETQ, residues 17–23) or modified versions of it. Researchers should confirm by mass spectrometry exactly which sequence they have, because results obtained with the full protein cannot be assumed for a fragment.

Why Is It Studied?

Because Tβ4 regulates actin dynamics, it is a natural tool for studying cell motility, cytoskeletal organization, and the behavior of migrating cells such as endothelial cells and keratinocytes. It has also drawn attention in developmental biology and cardiovascular research after studies in mouse models.

Research Background

Tβ4 was originally isolated from thymus tissue ("thymosin fraction 5") and later recognized as widely expressed. Foundational biochemistry in the 1990s characterized its actin-binding properties. Subsequent work, including a widely cited 2007 study in Nature, examined Tβ4 in mouse cardiac models and embryonic development.

The N-terminal tetrapeptide Ac-SDKP, which can be released from Tβ4 by prolyl oligopeptidase, is a separate bioactive peptide with its own research literature.

Evidence classification: Tβ4 findings are primarily from in vitro and animal studies. A limited number of early-phase human trials of full-length Tβ4 formulations have been registered or reported; they do not establish safety or efficacy, and no product has regulatory approval.

Mechanism and Scientific Principles

Actin sequestration

Tβ4 binds G-actin in a 1:1 complex, reducing polymerization. This is the best-established biochemical property and is supported by extensive in vitro biochemistry.

Cell migration and signaling

Cell studies report effects on migration of endothelial cells and keratinocytes, and interactions with signaling proteins such as integrin-linked kinase (ILK). These observations come from defined in vitro systems.

Fragment-specific activity

Different regions of the molecule have been associated with different activities in laboratory models; the actin-binding central domain and the Ac-SDKP N-terminus are the most frequently discussed.

What Laboratory Research Has Investigated

• Actin polymerization kinetics and binding stoichiometry (in vitro biochemistry).
• Endothelial and keratinocyte migration and tube-formation assays (in vitro).
• Cardiac and dermal models in mice and rats (animal).
• Developmental expression patterns in embryonic tissue (animal).

For comparison with a structurally unrelated peptide often discussed alongside it, see the BPC-157 Research Overview and BPC-157 vs TB-500.

Analytical and Experimental Considerations

At roughly 4.9 kDa, full-length Tβ4 is considerably larger than most short research peptides, which affects synthesis yield, impurity profile and analysis:

• Identity should be confirmed by high-resolution mass spectrometry; deletion sequences differ by single residues.
• Acetylation status of the N-terminus should be verified.
• Purity by HPLC should be interpreted alongside net peptide content — see Peptide Purity Explained.
• Always match the lot number on the COA to the vial; see How to Read a Peptide COA.

Limitations of Current Research

• Inconsistent nomenclature: "TB-500" may describe different sequences.
• Most functional data come from rodent and cell models.
• Findings with the full protein cannot be assumed for fragments, and vice versa.
• Human data are early-phase and limited.

Frequently Asked Questions

Scientific References

1. Huff T, Müller CS, Otto AM, Netzker R, Hannappel E. β-Thymosins, small acidic peptides with multiple functions. Int J Biochem Cell Biol. 2001;33(3):205-220. [Review / in vitro] View source (opens in new tab)
2. Goldstein AL, Hannappel E, Sosne G, Kleinman HK. Thymosin β4: a multi-functional regenerative peptide. Basic properties and clinical applications. Expert Opin Biol Ther. 2012;12(1):37-51. [Review] View source (opens in new tab)
3. Smart N, Risebro CA, Melville AA, et al. Thymosin β4 induces adult epicardial progenitor mobilization and neovascularization. Nature. 2007;445(7124):177-182. [Animal] View source (opens in new tab)
4. Bock-Marquette I, Saxena A, White MD, DiMaio JM, Srivastava D. Thymosin β4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair. Nature. 2004;432(7016):466-472. [In vitro / animal] View source (opens in new tab)